Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Ampullary cancer (ampulla of Vater), drawn from the whole corpus: 21 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No prospective randomised trial has compared subtype-directed adjuvant regimens; retrospective consortia and the NCCN guideline are the current basis.
Which patients with node-positive disease benefit from neoadjuvant therapy; extrapolation from pancreatic trials is being tested.
Surveillance intensity after Whipple and the role of ctDNA to select adjuvant therapy.
FAP-associated duodenal disease: timing of prophylactic surgery versus endoscopic control.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 9 changes by month →When this page itself was last checked or edited.
3-year overall survival 77.
Subtype-directed treatment recommendations formalised.
Six months of chemotherapy chosen by subtype: oxaliplatin-fluoropyrimidine (FOLFOX or CAPOX) for intestinal-type; gemcitabine-based or modified FOLFIRINOX for pancreatobiliary-type; evidence is from ESPAC-3 periampullary and retrospective series. (NCCN Category 2A)
Adjuvant chemotherapy after resection of periampullary cancer; survival benefit in adjusted analysis.
Median overall survival 23.